Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Scilex's ebitda for the twelve months ending Jun 30, 2026 was -$350.88M. For fiscal 2025 it was -$341.38M. The highest annual figure on record is -$31.48M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$341.38M | – |
| FY2024 | Dec 31, 2024 | -$79.35M | – |
| FY2023 | Dec 31, 2023 | -$101.29M | – |
| FY2022 | Dec 31, 2022 | -$46.67M | – |
| FY2021 | Dec 31, 2021 | -$32.06M | – |
| FY2020 | Dec 31, 2020 | -$31.48M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$109.50M | – |
| Q3 FY2025 | Sep 30, 2025 | -$185.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$27.37M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.91M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$37.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.71M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.86M | – |